Corporate partner Pablo Svirsky authored an article for the Indianapolis Business Journal titled, “Shipping Times for Some Supplies May Never Return to Old Levels,” that discusses the impact of pandemic-related supply chain challenges on the life sciences industry.
Svirsky explains that, even pre-pandemic, drug and medical device companies focused efforts on its supply chain and how potential disruptions might affect business. He notes that the key issue these days is figuring out which impacts of the last two years are here to stay.
In some cases, Svirsky says, it’s taking longer to make the product itself, and in other cases, part of the process has changed. He provides examples such as how pharmaceutical companies’ third-party manufacturers have had trouble securing vials for syringes due to increased demand. He adds that because the pandemic hit countries at different times, there is less predictability and more supply chain woes.
Lastly, Svirsky emphasizes that a lot of work remains to be done, but that it is clear the life sciences industry recognizes the problem and is working hard to overcome it.
The full article is available to Indianapolis Business Journal subscribers.